Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/87785
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Applied Biology and Chemical Technology | - |
dc.contributor | Chinese Mainland Affairs Office | - |
dc.creator | Lee, MML | - |
dc.creator | Chan, BD | - |
dc.creator | Wong, WY | - |
dc.creator | Qu, Z | - |
dc.creator | Chan, MS | - |
dc.creator | Leung, TW | - |
dc.creator | Lin, YS | - |
dc.creator | Mok, DKW | - |
dc.creator | Chen, SB | - |
dc.creator | Tai, WCS | - |
dc.date.accessioned | 2020-08-19T06:27:04Z | - |
dc.date.available | 2020-08-19T06:27:04Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/87785 | - |
dc.language.iso | en | en_US |
dc.publisher | Frontiers Research Foundation | en_US |
dc.rights | © 2020 Lee, Chan, Wong, Qu, Chan, Leung, Lin, Mok, Chen and Tai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY)(https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | en_US |
dc.rights | The following publication Lee MM-L, Chan BD, Wong W-Y, Qu Z, Chan M-S, Leung T-W, Lin Y, Mok DK-W, Chen S and Tai WC-S (2020) Anti-cancer Activity of Centipeda minima Extract in Triple Negative Breast Cancer via Inhibition of AKT, NF-κB, and STAT3 Signaling Pathways. Front. Oncol. 10:491 is available at https://dx.doi.org/10.3389/fonc.2020.00491 | en_US |
dc.subject | Centipeda minima | en_US |
dc.subject | Natural compounds | en_US |
dc.subject | Breast cancer | en_US |
dc.subject | Triple negative breast cancer (TNBC) | en_US |
dc.subject | Anti-cancer | en_US |
dc.title | Anti-cancer activity of centipeda minima extract in triple negative breast cancer via inhibition of AKT, NF-kappa B, and STAT3 signaling pathways | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.spage | 1 | - |
dc.identifier.epage | 15 | - |
dc.identifier.volume | 10 | - |
dc.identifier.doi | 10.3389/fonc.2020.00491 | - |
dcterms.abstract | Breast cancer is the most commonly diagnosed cancer in females worldwide. Estimates from the World Health Organization (WHO) International Agency for Research on Cancer, suggest that globally, there were around 2.1 million new breast cancer cases and 627,000 deaths due to breast cancer in 2018. Among the subtypes of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and carries the poorest prognosis, largest recurrence, and lowest survival rate. Major treatment options for TNBC patients are mainly constrained to chemotherapy, which can be accompanied by severe side effects. Therefore, development of novel and effective anti-cancer drugs for the treatment of TNBC are urgently required. Centipeda minima is a well-known traditional Chinese herbal medicine that has historically been used to treat rhinitis, sinusitis, relieve pain, and reduce swelling. Recent studies have shown that Centipeda minima exhibited efficacy against certain cancers, however, to date, no studies have been conducted on its effects in breast cancer. Here, we aimed to investigate the anti-cancer activity of the total extract of Centipeda minima (CME), and its underlying mechanism, in TNBC. In MDA-MB-231, we found that CME could significantly reduce cell viability and proliferation, induce apoptosis and inhibit cancer cell migration and invasion, in a dose and time-dependent manner. We showed that CME may potentially act via inhibition of multiple signaling pathways, including the EGFR, PI3K/AKT/mTOR, NF-kappa B, and STAT3 pathways. Treatment with CME also led to in vitro downregulation of MMP-9 activity and inhibition of metastasis. Further, we demonstrated that CME could significantly reduce tumor burden in MDA-MB-231 xenograft mice, without any appreciable side effects. Based on our findings, CME is a promising candidate for development as a therapeutic with high efficacy against TNBC. | - |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Frontiers in oncology, Apr. 2020, v. 10, 491, p. 1-15 | - |
dcterms.isPartOf | Frontiers in oncology | - |
dcterms.issued | 2020-04 | - |
dc.identifier.isi | WOS:000529925500001 | - |
dc.identifier.scopus | 2-s2.0-85083886688 | - |
dc.identifier.pmid | 32328465 | - |
dc.identifier.eissn | 2234-943X | - |
dc.identifier.artn | 491 | - |
dc.description.validate | 202008 bcrc | - |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_Scopus/WOS | en_US |
dc.description.pubStatus | Published | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Lee_Anti-Cancer_Centipeda_Minima.pdf | 2.17 MB | Adobe PDF | View/Open |
Page views
56
Last Week
0
0
Last month
Citations as of May 19, 2024
Downloads
18
Citations as of May 19, 2024
SCOPUSTM
Citations
30
Citations as of May 16, 2024
WEB OF SCIENCETM
Citations
29
Citations as of May 16, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.